BLRX

BioLineRx Ltd.

0.64 USD
+0.03 (+4.83%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioLineRx Ltd. stock is down 0% since 30 days ago. The next earnings date is May 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 46.15% of the previous 12 May’s closed higher than April.

About BioLineRx Ltd.

Motixafortide, a peptide, has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization. It is also developing AGI-134, an immuno-oncology agent, and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.